Literature DB >> 11737333

Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy.

M A French1, N Lenzo, M John, S A Mallal, E J McKinnon, I R James, P Price, J P Flexman, M L Tay-Kearney.   

Abstract

BACKGROUND: To determine if infectious disease events in HIV-infected patients treated with highly active antiretroviral therapy (HAART) are a consequence of the restoration of pathogen-specific immune responses, a single-centre retrospective study of all HIV-infected patients commencing HAART prior to 1 July 1997 was undertaken to determine the incidence, characteristics and time of onset of disease episodes in HAART responders (decrease in plasma HIV RNA of > 1 log10 copies/mL).
METHODS: Baseline and post-therapy changes in CD4 T-cell counts and HIV RNA were compared in patients with and without disease and delayed-type hypersensitivity responses to mycobacterial antigens were measured in selected patients.
RESULTS: Thirty-three of 132 HAART responders (25%) exhibited one or more disease episodes after HAART, related to a pre-existent or subclinical infection by an opportunistic pathogen. Disease episodes were most often related to infections by mycobacteria or herpesviruses but hepatitis C virus (HCV), molluscum contagiosum virus and human papilloma virus were also implicated. They were most common in patients with a baseline CD4 T-cell count of < 50/uL and occurred most often during the first 2 months of therapy and when CD4 T-cell counts were increasing. Mycobacteria- and HCV-related diseases were associated with restoration of pathogen-specific immune responses.
CONCLUSIONS: We conclude that improved immune function in immunodeficient patients treated with HAART may restore pathogen-specific immune responses and cause inflammation in tissues infected by those pathogens.

Entities:  

Mesh:

Year:  2000        PMID: 11737333     DOI: 10.1046/j.1468-1293.2000.00012.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  99 in total

1.  [Immune reconstitution syndrome].

Authors:  D Meyer-Olson; D Ernst; M Stoll
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

Review 2.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

3.  Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children.

Authors:  Thanyawee Puthanakit; Peninnah Oberdorfer; Noppadon Akarathum; Pornphun Wannarit; Thira Sirisanthana; Virat Sirisanthana
Journal:  Pediatr Infect Dis J       Date:  2006-01       Impact factor: 2.129

Review 4.  Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.

Authors:  Monika Müller; Simon Wandel; Robert Colebunders; Suzanna Attia; Hansjakob Furrer; Matthias Egger
Journal:  Lancet Infect Dis       Date:  2010-04       Impact factor: 25.071

5.  Fatal tuberculous meningitis caused by immune restoration disease.

Authors:  Hagen B Huttner; Rainer Kollmar; Andreas Hug; Fabian Meisel; Bodo Kress; Stefan Schwab
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

6.  Impact of the immune reconstitution inflammatory syndrome (IRIS) on mortality and morbidity in HIV-infected patients in Mexico.

Authors:  Irma Hoyo-Ulloa; Pablo F Belaunzarán-Zamudio; Brenda Crabtree-Ramirez; Arturo Galindo-Fraga; María Eugenia Pérez-Aguinaga; Juan G Sierra-Madero
Journal:  Int J Infect Dis       Date:  2011-04-13       Impact factor: 3.623

7.  Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome.

Authors:  Shuli Bonham; David B Meya; Paul R Bohjanen; David R Boulware
Journal:  Biomark Med       Date:  2008       Impact factor: 2.851

8.  Hospitalization risk following initiation of highly active antiretroviral therapy.

Authors:  S A Berry; Y C Manabe; R D Moore; K A Gebo
Journal:  HIV Med       Date:  2009-12-08       Impact factor: 3.180

Review 9.  Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy.

Authors:  Sarah M Kranick; Avindra Nath
Journal:  Continuum (Minneap Minn)       Date:  2012-12

10.  Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: results from the TREAT Asia HIV observational database.

Authors:  H Byakwaga; K Petoumenos; J Ananworanich; F Zhang; M A Boyd; T Sirisanthana; P C K Li; C Lee; C V Mean; V Saphonn; S F S Omar; S Pujari; P Phanuphak; P L Lim; N Kumarasamy; Y M A Chen; T P Merati; S Sungkanuparph; R Ditangco; S Oka; G Tau; J Zhou; M G Law; S Emery
Journal:  J Int Assoc Provid AIDS Care       Date:  2013-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.